Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × baricitinib × Lymphoid × Clear all
NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
271 enrolled 32 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡